Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Cited by 119 Publications

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell, 2011, 145(4):529-42

PubMed: 21565612 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Cancer Res, 2019, 79(8):2031-2041

PubMed: 30824588 ( click the link to review the publication )

Int J Cancer, 2019, 144(7):1685-1696

PubMed: 30478958 ( click the link to review the publication )

Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):90

PubMed: 30786932 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):431-445

PubMed: 30401718 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(1):42-53

PubMed: 30201826 ( click the link to review the publication )
Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.06.022

PubMed: 31251940 ( click the link to review the publication )

J Biol Chem, 2019, 294(2):397-404

PubMed: 30478172 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-018-00717-9

PubMed: 30612311 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(2):620-625

PubMed: 30522863 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(4):1098-1101

PubMed: 30277116 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):75-84

PubMed: 30431088 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )

Br J Cancer, 2018, 119(11):1392-1400

PubMed: 30425352 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1167-1176

PubMed: 29626126 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2206-2216

PubMed: 29970481 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1837-1846

PubMed: 30323975 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Anal Biochem, 2018, 543:132-139

PubMed: 29247608 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )
Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(5):1236-46

PubMed: 25777962 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )

Cell, 2015, 161(7):1592-605

PubMed: 26052046 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )
Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )

Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )

Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )
J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )

Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	NX7C[Ip6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW0JIQ>		NF;ScGtKSzVyPUWuO\|A2KCEQvF2g	Mn;2NVg2PTl4MUO=
KP6.3	M3jacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkPyOEBl		M{LuZWlEPTB;MUCuOFI5KM7:TTC=	Mlj5NVg2PTl4MUO=
KP7.7	NHu2[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnK2OEBl		MWHJR\|UxRTV5IH7NJC=>	M4H1cVE5PTV7NkGz
KB2P3.4	NFLicJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NE[yU5M1KGR?		M3K3RmlEPTB;MUK0JG0h	MXqxPFU2QTZzMx?=
KB2P1.21	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M160UVQh\A>?		NEG0cJJKSzVyPUi5NFchdk1i	M2G1NFE5PTV7NkGz
U373-MG	NYLNVFlmS3m2b4TvfIlkKEG\|c3H5	M4DqSFEh\|ryPIB?=	M{D2flI1KGh?		NGjhNmVKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	M{f4elE5QTV2N{Gy
T98G	MkP6R5l1d3SxeHnjJGF{e2G7	M4iyWlEh\|ryPIB?=	NG\UVYszPCCq		MX3JcoNz\WG\|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6	NXu2U3BTOTh7NUS3NVI>
U87-MG	NVHDU5VtS3m2b4TvfIlkKEG\|c3H5	M3rHfFEh\|ryPIB?=	NF3FbmszPCCq		M4H0R2lv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl?	MY[xPFk2PDdzMh?=
UVW	M1;x[GN6fG:2b4jpZ{BCe3OjeR?=	NFOxcoM2ODBibl2=	MorXNlQhcA>?		NGDDbnFKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	MojLNVg6PTR5MUK=
HeLa	NEDu[YtHfW6ldHnvckBCe3OjeR?=	MkWxOVAxKG6P	MWe0JIg>		MXXDZZV{\XNiYTDtc4Rme3RiZHXsZZkhcW5icnXqc4lvcW6pIH;mJJJi\GmjdHnvck1qdmS3Y3XkJGRPSSCkcnXhb5M>	MXyxPFk2PDdzMh?=
HeLa	NX3UXHp7TnWwY4Tpc44hSXO\|YYm=	NX7lV4JEOSEQvF2g	NV;WdnBIOjRiaB?=		Mk[1SY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG\|ZTDhdpJme3R?	MUmxPFk2PDdzMh?=
T98G	Mlr6SpVv[3Srb36gRZN{[Xl?	MmD0NUDPxE1i	M4rWeFI1KGh?		MlXNSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG\|ZTDhdpJme3R?	NVXGO2FOOTh7NUS3NVI>
L3	Mn76R5l1d3SxeHnjJGF{e2G7	Mli5OUDPxE1i	MYW5OkBp	NWf2WJNoTE2VTx?=	MWPTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=	Mk\2NlAyOjR2NUm=
Granta-519	MonUR5l1d3SxeHnjJGF{e2G7	MUG1JO69VSB?	MoDaPVYhcA>?	M1fWfGROW09?	NWHIRW1SW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	MofoNlAyOjR2NUm=
BT	NWj1OlljS3m2b4TvfIlkKEG\|c3H5	Mon5OUDPxE1i	NEjWN406PiCq	NYm0UYNvTE2VTx?=	NX35XWd1W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	M17FUFIxOTJ2NEW5
UPN2	MkPmR5l1d3SxeHnjJGF{e2G7	M{GwbVUh\|ryPIB?=	NGfsS2Y6PiCq	NHOyWm5FVVOR	NIHQU4tUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	NGLkfIozODF{NES1PS=>
HBL-2	NXO0WVJ6S3m2b4TvfIlkKEG\|c3H5	M4jpVFUh\|ryPIB?=	MojaPVYhcA>?	MnXGSG1UVw>?	NY\vSXI4W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	MofyNlAyOjR2NUm=
JVM-2	M3HPXmN6fG:2b4jpZ{BCe3OjeR?=	NIDMZnY2KM7:TTC=	NIfmSmc6PiCq	NXPENJFOTE2VTx?=	Mk\YV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	MUiyNFEzPDR3OR?=
Z138	NUGwSWdmS3m2b4TvfIlkKEG\|c3H5	MWq1JO69VSB?	MmP2PVYhcA>?	M{S2bWROW09?	NVO1RmhXW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	M4fHblIxOTJ2NEW5
RWPE	M{jXd2lvfmG\|aY\lJGF{e2G7	NV:zRYNGOjVizszN	NIPrRpo1QCCq	NF7zSWFFVVOR	NYLhUnNrW2mpbnnmbYNidnSueTDy[YR2[2W\|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>?	M3H3[FIyPTd3OE[1
VCaP	MkfsTY53[XOrdnWgRZN{[Xl?	M2njblI2KM7:TR?=	M161W\|Q5KGh?	NVLHe4p[TE2VTx?=	NHeyS5FUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v	M2XTWFIyPTd3OE[1
Mouse H2AX−/− ES Cells	MXfDfZRwfG:6aXOgRZN{[Xl?	MWKyMlUh\|ryP	MlnuNlAhcA>?		NF3UZXdUcWewaX\pZ4FvfGy7IHnubIljcXS\|IHPlcIwhe3W{dnn2ZYw>	NH\zbWEzOzN3NUS4PS=>
Mouse ATM−/− ES Cells	NXSyXnBnS3m2b4TvfIlkKEG\|c3H5	M{LLUlIvPSEQvF2=	MoDZNlAhcA>?		M{jrXXNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=>	M3W4S\|I{OzV3NEi5
H1650	NYXPTmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{X5XVIxKM7:TR?=	MXSxOFQhcA>?		NWnN[nRiUUN3ME2xOU41PyEQvF2=	M{jlcFI{OjN7OEC5
H1650PTEN+	NHXvbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWCxc3dYOjBizszN	MVuxOFQhcA>?		NYHWeJJSUUN3ME21NE45OyEQvF2=	Ml7qNlMzOzl6MEm=
PC-9	NIPMUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlOzNlAh\|ryP	M1W1VlE1PCCq		NIT0VodKSzVyPUWuPFgh\|ryP	MormNlMzOzl6MEm=
PC-9PTEN−	NX\POoU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHrdGtZOjBizszN	NE\QW3UyPDRiaB?=		MoL0TWM2OD14LkWyJO69VQ>?	MW[yN\|I{QThyOR?=
MDA-MB-231	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHnVVVA2KGSjeR?=		NE\BU21KSzVyPU[uPUDPxE1?	NVzab2kzOjN5NkC0PVY>
MDA-MB-468	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33BbFUh\GG7		NHi3S2FKSzVyPUWuNEDPxE1?	NFfBZYkzOzd4MES5Oi=>
BT20	M2r6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1H4XVUh\GG7		M3yxW2lEPTB;Nz63JO69VQ>?	NX;WN5U1OjN5NkC0PVY>
HCC1143	NGrZSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmfZOUBl[Xl?		MmXXTWM2OD1zMT6xJO69VQ>?	MVWyN\|c3ODR7Nh?=
HCC1937	NVz5OnhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHLxfJI2KGSjeR?=		M{jRemlEPTB;MUKuOkDPxE1?	MXSyN\|c3ODR7Nh?=
Hs578t	M3vibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXy1JIRigQ>?		MkflTWM2OD13Lk[g{txO	NVHZO4N{OjN5NkC0PVY>
Hs578t(si)	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX62U3pGPSCmYYm=		MmfnTWM2OD15LkWg{txO	MYeyN\|c3ODR7Nh?=
BT474	NGL3PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml;iOUBl[Xl?		MkToTWM2OD1zOT64JO69VQ>?	NIXxSWwzOzd4MES5Oi=>
JIMT1	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV7zWVVmPSCmYYm=		MVrJR\|UxRTdwNzFOwG0>	NIG2PJozOzd4MES5Oi=>
SKBR3	NVHLcmd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mk\1OUBl[Xl?		NXTXZllYUUN3ME2xNU4yKM7:TR?=	MXWyN\|c3ODR7Nh?=
SUM159	Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEnsNGo2KGSjeR?=		M3HndmlEPTB;ND6yJO69VQ>?	M2fkW\|I{PzZyNEm2
CAMA1	NHzCXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVy1JIRigQ>?		NFLlVnRKSzVyPUG1Mlgh\|ryP	MYmyN\|c3ODR7Nh?=
MCF7	NV3Gc\|AxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2DmT\|Uh\GG7		NVjuT2pwUUN3ME21Mlgh\|ryP	MlrJNlM4PjB2OU[=
T47D	NYrkbXZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWq3Npg5PSCmYYm=		MkL1TWM2OD17Lk[g{txO	NHrCW5YzOzd4MES5Oi=>
HCT116	NHrSOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6xNFAh\|ryP	M3m3dlQ5KGh?	NHXGN2VFVVOR	NFm2O\|BKSzVyPUKuOUDPxE1i	MUiyOFU4Pzl2MR?=
SW1116	M{PuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4THWlExOCEQvF2=	M4q3NFQ5KGh?	NGTKU4FFVVOR	M{nZU2lEPTB;MUCwJO69VQ>?	MnjLNlQ2Pzd7NEG=
HT29	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjBVmRYOTByIN88US=>	NVPrNlM5PDhiaB?=	M1HiUWROW09?	MXHJR\|UxRTF2Lkeg{txO	MoPTNlQ2Pzd7NEG=
LoVo	NUK1bmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV6xNFAh\|ryP	M3zwWVQ5KGh?	NGnlSGZFVVOR	MYLJR\|UxRTF\|LkSg{txO	NUDMN2d7OjR3N{e5OFE>
HCT-15	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUmxNFAh\|ryP	Ml;KOFghcA>?	NYj5T\|A4TE2VTx?=	NYnab5pKUUN3ME2xNEDPxE1?	NXG4VlhsOjR3N{e5OFE>
SW48	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzoZ\|YyODBizszN	MXG0PEBp	M2LCb2ROW09?	NV[2blNUUUN3ME25MlUh\|ryP	MnHhNlQ2Pzd7NEG=
C-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHKc4IyODBizszN	M13k[lQ5KGh?	NWr4bGZ4TE2VTx?=	M3;BSWlEPTB;Nz62JO69VQ>?	NHzqU5QzPDV5N{m0NS=>
RKO	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTlNVAxKM7:TR?=	NIru[HA1QCCq	M1\6eGROW09?	Mn\0TWM2OD13Lkmg{txO	NWfwT2NkOjR3N{e5OFE>
HCT116	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUOxNFAh\|ryP	MW[0PEBp	MXfEUXNQ	NF7vdXhRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli	M2nzOFI1PTd5OUSx
SW1116	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P4[VExOCEQvF2=	M3foZ\|Q5KGh?	MXPEUXNQ	M2G4UXBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	M2HoNlI1PTd5OUSx
HT29	NI\qTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\oZlYyODBizszN	M3LzUVQ5KGh?	NGXETFJFVVOR	MXnQc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	MX:yOFU4Pzl2MR?=
LoVo	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvPOHQyODBizszN	M4LtOVQ5KGh?	NH70eWxFVVOR	MWHQc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	NGP6emszPDV5N{m0NS=>
SW48	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUixNFAh\|ryP	M2\RSVQ5KGh?	NVO2S\|J2TE2VTx?=	MV7Qc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	M3zIeFI1PTd5OUSx
C-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfTfo1vOTByIN88US=>	NIe1WVE1QCCq	MmLzSG1UVw>?	MnLVVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	Mlj6NlQ2Pzd7NEG=
RKO	NF3VU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M133bVExOCEQvF2=	MlHLOFghcA>?	Ml;qSG1UVw>?	M4LONnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	Ml\TNlQ2Pzd7NEG=
HCT116	M4SzO2Z2dmO2aX;uJGF{e2G7	MnLoNVAhdk1?	MV[xNkBp	Mn3ZSG1UVw>?	MkexTY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6	MVmyOFU4Pzl2MR?=
HT29	MoXrSpVv[3Srb36gRZN{[Xl?	NYPYXVQ4OTBibl2=	NEW4UHAyOiCq	M3LrTWROW09?	NH3oXpVKdmO{ZXHz[ZMhTE6DIHTveYJt\S2\|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i=	NVH2dVlvOjR3N{e5OFE>
TE-6	Mny3SpVv[3Srb36gRZN{[Xl?	NXvOPVU1PSEQvF2g	Ml;KNVIhcA>?	NYfkV5Z7TE2VTx?=	MoPVTY5lfWOnczDHNk9OKGG{cnXzeC=>	MoXQNlQzOTlzNkS=
TE-6	M4nOUWZ2dmO2aX;uJGF{e2G7	MkjQOUDPxE1i	NVnnUJR{OjRiaB?=	MYrEUXNQ	NXf0OlZrUW6lcnXhd4V{KGmwIHTveYJt\SC\|dILhcoQh[nKnYXvzJEhFW0K\|KR?=	MUmyOFIyQTF4NB?=
Hep3B	M4j4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX20NEDPxE1i	NWLRVpRUPzJiaB?=	MkDOSG1UVw>?	M2XlZXN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS	MoTWNlUxPzJ5NUK=
Huh7	M2joe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYO0NEDPxE1i	NIf6Zok4OiCq	NIL0fYxFVVOR	MXTTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=>	NXLXN2o3OjVyN{K3OVI>
Hep3B	M3exfmZ2dmO2aX;uJGF{e2G7	M1rkZVQxKM7:TTC=	NFG3e2kzPCCq	NWDZOW1bTE2VTx?=	NV72eHhDUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR	MlrHNlUxPzJ5NUK=
Huh7	NGPZ[XBHfW6ldHnvckBCe3OjeR?=	M1nrSVQxKM7:TTC=	M1rqT\|I1KGh?	M{PMT2ROW09?	NVzvT4FDUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR	NIT5WZAzPTB5Mke1Ni=>
Hep3B	M1LOcGZ2dmO2aX;uJGF{e2G7	M4nnNFQxKM7:TTC=	NICz[IUzPCCq	NGLmS2VFVVOR	M{X6Wmlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?=	MVWyOVA4Ojd3Mh?=
Huh7	M3Xid2Z2dmO2aX;uJGF{e2G7	MnzHOFAh\|ryPIB?=	MWGyOEBp	M4\qS2ROW09?	NXnH[4xOUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR	MX6yOVA4Ojd3Mh?=
SGC-7901	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPOOVFEOzEEoN88US=>	MYq0PEBp	Mo\nSG1UVw>?	NGm1fVBDdG:lazDvfIFtcXCuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg>	MljLNlU4PjdyN{[=
COLO-800	M3qxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPaXmtWUUN3ME2wMlQ1OTZ2IN88US=>	NW\zOm9JW0GQR1XS
EoL-1-	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;NSVlKSzVyPUCuOVY1PDZizszN	MVrTRW5ITVJ?
NCI-H209	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTBwOUG1OVYh\|ryP	NWfnRYlWW0GQR1XS
ES1	M2CwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmL0TWM2OD1zLkGxOFA5KM7:TR?=	MVHTRW5ITVJ?
NKM-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTsTWM2OD1zLkK1N\|Q4KM7:TR?=	MWXTRW5ITVJ?
NTERA-S-cl-D1	NHTwOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rDNmlEPTB;MT6zN\|M1OSEQvF2=	Mk\6V2FPT0WU
MHH-ES-1	NFvUVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13FNWlEPTB;MT62NlA3PyEQvF2=	Mn7OV2FPT0WU
ES8	MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnn1TWM2OD1zLkeyOFE1KM7:TR?=	MkPGV2FPT0WU
NCI-H720	NVPNPW51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTJwMkC2PVkh\|ryP	NGe5VnNUSU6JRWK=
EW-3	NEGwZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTJwMke1N\|Qh\|ryP	M3;FcnNCVkeHUh?=
D-566MG	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV75bVRjUUN3ME2yMlQ1PTZ6IN88US=>	MXzTRW5ITVJ?
697	NXWzUow2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJwOESxO\|Mh\|ryP	MUjTRW5ITVJ?
ES5	NXjvXWxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXGOGpKSzVyPUKuPFgyQDlizszN	M{Lr[nNCVkeHUh?=
COLO-684	NFfKcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnjTWM2OD1\|LkWxOlk3KM7:TR?=	M{PIZXNCVkeHUh?=
ML-2	NILPc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTNwNkCwOVgh\|ryP	NF[xcopUSU6JRWK=
MC-IXC	NV3pUmJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFztN2lKSzVyPUOuOlM{QTNizszN	MWfTRW5ITVJ?
DB	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrETWM2OD1\|Lk[1OFQ5KM7:TR?=	MYTTRW5ITVJ?
HCC2218	NYr0VG92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G2[WlEPTB;Mz63N\|ExOyEQvF2=	NWfEbnpzW0GQR1XS
NCI-H510A	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzP[GZKSzVyPUOuPFI4OjRizszN	NV3Sd4lwW0GQR1XS
NCI-H526	NW\6b3ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXrTWM2OD1\|Lki2PVU5KM7:TR?=	NUDQU4NQW0GQR1XS
MV-4-11	M{[5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PrdmlEPTB;ND6xN\|M{PCEQvF2=	NVr0NHYzW0GQR1XS
PA-1	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTRwMkWyPUDPxE1?	NHPacIRUSU6JRWK=
EW-22	NFvyZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[zTWM2OD12LkO1PFYh\|ryP	M13CcHNCVkeHUh?=
KASUMI-1	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvRcGhKSzVyPUSuOFAyODlizszN	NYHtblNVW0GQR1XS
LU-139	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfXTWM2OD12Lke1PFI6KM7:TR?=	NU\uR5AzW0GQR1XS
SBC-1	NXXxc\|NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX3[4tKSzVyPUSuPFA6ODhizszN	MkH6V2FPT0WU
H4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnUdmhpUUN3ME20Mlg6PDR\|IN88US=>	MYjTRW5ITVJ?
EW-11	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjQOYFXUUN3ME21MlA5ODd{IN88US=>	MmWxV2FPT0WU
NBsusSR	M2fwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzjPI1KSzVyPUWuNVIxPTVizszN	NUexdGlJW0GQR1XS
RPMI-8226	NYXMUIIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPJUlhKSzVyPUWuNVUzPDRizszN	NF3KR25USU6JRWK=
DEL	Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2e3cmlEPTB;NT6yNFAxPiEQvF2=	M3H5b3NCVkeHUh?=
ES4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3QTopwUUN3ME21MlUyOzh7IN88US=>	NHTSbnNUSU6JRWK=
GCT	NEfm[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHCbVlKSzVyPUWuOVY5PTZizszN	MX7TRW5ITVJ?
NCI-H1048	NXXWXmpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPy[3VRUUN3ME21Mlk4Ojd\|IN88US=>	NFrV[WpUSU6JRWK=
NCI-SNU-1	M3zMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mni1TWM2OD14LkCyNkDPxE1?	M2\5OnNCVkeHUh?=
ES7	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7TTIw1UUN3ME22MlA{PTd5IN88US=>	NEfZcZFUSU6JRWK=
SW982	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTZwMEmxN\|ch\|ryP	MnjQV2FPT0WU
L-363	M{LHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUG3XWc{UUN3ME22MlM{QTd2IN88US=>	NUPjZmxoW0GQR1XS
HT-1080	M330[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TJR2lEPTB;Nj60PVY5OyEQvF2=	NHXnSplUSU6JRWK=
HAL-01	NIPkco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoGyTWM2OD14LkWxNFkh\|ryP	MkP3V2FPT0WU
NB14	M3LW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvDe3RiUUN3ME22MlY1ODN7IN88US=>	MVzTRW5ITVJ?
EW-13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn5SYVKSzVyPU[uO\|c1OjRizszN	NY\ORolwW0GQR1XS
NY	NG\FW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fTW2lEPTB;Nj65OFYxPSEQvF2=	M4riXHNCVkeHUh?=
NCI-SNU-5	M4C3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTdwMUC0N\|Mh\|ryP	Mke4V2FPT0WU
MS-1	M1:4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TKRWlEPTB;Nz6xO\|Q6PCEQvF2=	MU\TRW5ITVJ?
EW-16	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTRTWM2OD15LkOxPFYyKM7:TR?=	NV3JWHpXW0GQR1XS
LU-65	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTdwNEi0NVch\|ryP	NF60ZXZUSU6JRWK=
HGC-27	M2\zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHETWM2OD15LkeyNVc{KM7:TR?=	NUm1T5ZHW0GQR1XS
CTB-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;SU2lEPTB;Nz63OlE4PSEQvF2=	NXuzU2o{W0GQR1XS
5637	NIPJe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X6eGlEPTB;Nz65Nlg3KM7:TR?=	MoW1V2FPT0WU
U251	NU\6b4x{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTdwOUSwNVYh\|ryP	NV\ySJAyW0GQR1XS
HOS	M2\uWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe4NlFKSzVyPUiuNlMxODdizszN	NVX1NGczW0GQR1XS
DOHH-2	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknNTWM2OD16LkKzOVgh\|ryP	NHvwPGNUSU6JRWK=
EW-1	M{DycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlv4TWM2OD16LkOwNFg5KM7:TR?=	MYrTRW5ITVJ?
BV-173	NFTuPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[zO2lEPTB;OD61OVU1KM7:TR?=	MlXjV2FPT0WU
8-MG-BA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfiUFdKSzVyPUiuOlg6QDhizszN	NXz2NW9oW0GQR1XS
NB69	M2HxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jzeWlEPTB;OD63NFkzOSEQvF2=	MlThV2FPT0WU
NCI-H69	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjqcJhKSzVyPUmuPVA6PjFizszN	NYDsUItPW0GQR1XS
RS4-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33GbWlEPTB;MUGuNlIxQCEQvF2=	Mn71V2FPT0WU
ONS-76	M3XhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnPTWM2OD1zMT6yPVQ4KM7:TR?=	MXnTRW5ITVJ?
SF539	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nFO2lEPTB;MUGuOFg5QSEQvF2=	M4HPUnNCVkeHUh?=
HuO-3N1	NGfPXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3:w[mlEPTB;MUGuOVc6PiEQvF2=	MlLrV2FPT0WU
NCI-H1651	NVLEbI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHf6R4dKSzVyPUGyMlMyOTVizszN	M4[yS3NCVkeHUh?=
KARPAS-45	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXKTWM2OD1zMj6zO\|Yh\|ryP	MV\TRW5ITVJ?
SK-NEP-1	NYX6SVNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13RWmlEPTB;MUKuOFYxQSEQvF2=	NUPHVIlNW0GQR1XS
LAMA-84	NGryZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPkTWM2OD1zMz6xNFk2KM7:TR?=	M1zJcHNCVkeHUh?=
NCI-H1155	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17De2lEPTB;MUOuNlg2PiEQvF2=	MWDTRW5ITVJ?
CTV-1	M131[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDVWHVKSzVyPUGzMlQ1PSEQvF2=	Mo\hV2FPT0WU
QIMR-WIL	M4nFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1L4eWlEPTB;MUOuO\|gyPCEQvF2=	MljmV2FPT0WU
H9	NUnYWHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnryTWM2OD1zMz64OFc2KM7:TR?=	NGXLR2lUSU6JRWK=
SK-MEL-1	NVW2[FFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4q5OGlEPTB;MUOuPVM1PyEQvF2=	M2TCNnNCVkeHUh?=
HD-MY-Z	NIXSSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITzRnhKSzVyPUG0MlA3OzdizszN	M4HMeXNCVkeHUh?=
TI-73	M1T5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF2LkKzOVYh\|ryP	NHG0TVhUSU6JRWK=
JVM-3	M{\HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\5fGtKSzVyPUG1MlU4OTZizszN	MW\TRW5ITVJ?
D-247MG	M2HYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzaPYpKSzVyPUG1MlU6OyEQvF2=	MUfTRW5ITVJ?
VA-ES-BJ	NXrXNodbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1m2RWlEPTB;MUWuOlA6PyEQvF2=	MV3TRW5ITVJ?
NOS-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIq2WnFKSzVyPUG1MlY2OjJizszN	NFXlO41USU6JRWK=
MOLT-4	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTEcXc{UUN3ME2xOk44PTJizszN	MmXnV2FPT0WU
Mo-T	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlToTWM2OD1zNz6wPFQ6KM7:TR?=	M1jPNHNCVkeHUh?=
NCI-H1770	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn[yTWM2OD1zNz6xOVQ{KM7:TR?=	Ml[wV2FPT0WU
COLO-320-HSR	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnz0TWM2OD1zNz6xPFI4KM7:TR?=	NYfjVVhCW0GQR1XS
TE-12	NFWxRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEX5e5RKSzVyPUG3MlcxPTRizszN	Mlm2V2FPT0WU
NCI-H82	M3fWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnWTWxKSzVyPUG3Mlg4OjhizszN	NUjJOlZnW0GQR1XS
NEC8	NFXDfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPRfIhKSzVyPUG4MlE{OTZizszN	MkGwV2FPT0WU
HSC-3	M4TGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLWTWM2OD1zOD63OFE1KM7:TR?=	NXzCbGxLW0GQR1XS
NCI-H1092	NGS4T\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTF6Lke1PVUh\|ryP	NUHPd5FPW0GQR1XS
NCI-H292	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33WNmlEPTB;MUmuNFQ5QSEQvF2=	NFi1OlBUSU6JRWK=
L-428	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTXVHRtUUN3ME2xPU42PTlizszN	MU\TRW5ITVJ?
LU-134-A	NVO3XppPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTF7LkW3NkDPxE1?	MnXSV2FPT0WU
GI-ME-N	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2m3[GlEPTB;MUmuOVc1PyEQvF2=	Mor1V2FPT0WU
ALL-PO	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPvTWM2OD1zOT61PVczKM7:TR?=	NYnMR49[W0GQR1XS
D-283MED	NFjGR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTF7LkmxOUDPxE1?	NVPhWnBVW0GQR1XS
D-423MG	NFH6[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXr3bpB{UUN3ME2xPU46QTZ5IN88US=>	MVrTRW5ITVJ?
CAKI-1	NEjnNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjlS\|Z6UUN3ME2yNE4zOjF7IN88US=>	MlPRV2FPT0WU
ETK-1	NWL4dJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnmTWM2OD1{MD6yOlE2KM7:TR?=	MmK1V2FPT0WU
G-402	M{DvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfmeoNSUUN3ME2yNE42OzN2IN88US=>	M4mwVHNCVkeHUh?=
HL-60	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1K1d2lEPTB;MkGuNVYyOyEQvF2=	NHPlOZZUSU6JRWK=
A2058	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTJzLkS0O\|ch\|ryP	NUjabVhLW0GQR1XS
CHP-212	MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfxTWM2OD1{MT65NFUyKM7:TR?=	NX3ncZdCW0GQR1XS
KY821	M2Xsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3jTWM2OD1{MT65O\|Uh\|ryP	NVztOFZ5W0GQR1XS
TYK-nu	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLaO4FNUUN3ME2yNk4xPjVzIN88US=>	NILYZVhUSU6JRWK=
JVM-2	M{DieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJ{LkK5PFMh\|ryP	MknpV2FPT0WU
KU812	M3;ESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnRcWVwUUN3ME2yNk44OzF{IN88US=>	NGPoXFdUSU6JRWK=
MKN28	M4mxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LPS2lEPTB;MkKuPVAyPSEQvF2=	MX\TRW5ITVJ?
ECC10	M1TUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJ\|Lke0NUDPxE1?	MlvlV2FPT0WU
BHT-101	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTJ2LkCwNFgh\|ryP	MYnTRW5ITVJ?
DU-4475	NWfqcW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDUb49KSzVyPUK0MlM{OzdizszN	NED2UWZUSU6JRWK=
769-P	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHmWmpKSzVyPUK0Mlg1PjZizszN	NGPweGpUSU6JRWK=
HEC-1	NILwWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHvWINVUUN3ME2yOU41PDVizszN	Mo\jV2FPT0WU
MOLT-13	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPZNoJKSzVyPUK1MlU{OzFizszN	M{SwdnNCVkeHUh?=
8505C	NUHzfpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDWTWM2OD1{Nj60PVc4KM7:TR?=	MnO2V2FPT0WU
GB-1	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPQU\|AxUUN3ME2yOk44OTd4IN88US=>	NWC3fpF4W0GQR1XS
SF126	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2K1TWlEPTB;Mk[uO\|Y1QCEQvF2=	MV;TRW5ITVJ?
A4-Fuk	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoGzTWM2OD1{Nz6xNlcyKM7:TR?=	MlztV2FPT0WU
OVCAR-8	M{POZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zJU2lEPTB;MkeuNVU{QSEQvF2=	NFzFfnJUSU6JRWK=
NCI-H1304	M4Pnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFv0XGtKSzVyPUK3MlU1KM7:TR?=	MnrjV2FPT0WU
GR-ST	NHnYOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XJbmlEPTB;MkiuNFQ4KM7:TR?=	NHHzR5BUSU6JRWK=
G-401	NWLhNJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XXW2lEPTB;MkiuOVA6PiEQvF2=	MlL6V2FPT0WU
LXF-289	NYPPSYVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJ6LkW2OVEh\|ryP	NEnkRWtUSU6JRWK=
DBTRG-05MG	MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDnTWM2OD1{OD65NlA1KM7:TR?=	MXPTRW5ITVJ?
YKG-1	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;OTWM2OD1{OT64Olgh\|ryP	MW\TRW5ITVJ?
GAMG	NVHDcWs4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLsSpJKSzVyPUK5Mlk6OyEQvF2=	Moi2V2FPT0WU
HCT-116	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnwdHlKSzVyPUOwMlA2PDhizszN	M4TGeXNCVkeHUh?=
S-117	NV2yfWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\GPWlbUUN3ME2zNU4zOjV5IN88US=>	NUTHdYgyW0GQR1XS
NCI-H1693	NF2xNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\1cGlEPTB;M{OuOlU1OiEQvF2=	MULTRW5ITVJ?
A427	NUG1WJp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUm0em5JUUN3ME2zN{46QTd4IN88US=>	Mme5V2FPT0WU
HT-29	NX;LSVhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFm2S2hKSzVyPUO0MlYxOzJizszN	M{HkXnNCVkeHUh?=
P12-ICHIKAWA	NUf6VW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfMTWM2OD1\|ND63OFkyKM7:TR?=	MWrTRW5ITVJ?
CAL-51	NFjlNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTN3LkC3NFkh\|ryP	NVfMUoZSW0GQR1XS
Ramos-2G6-4C10	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDwTWM2OD1\|NT6yOFI2KM7:TR?=	M1;NcnNCVkeHUh?=
SCH	NEfRR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDB[Y5zUUN3ME2zOk41OTd2IN88US=>	Ml3vV2FPT0WU
SK-MEL-24	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[x[nVxUUN3ME2zOk46ODR2IN88US=>	NELRfZdUSU6JRWK=
SW1573	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkH1TWM2OD1\|OD63NlE3KM7:TR?=	NUnpUWQyW0GQR1XS
BALL-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHNSJBQUUN3ME2zPU4zOTJ7IN88US=>	NFviTVVUSU6JRWK=
BE-13	NF36VHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LqPWlEPTB;M{muN\|I6KM7:TR?=	NGLDd5pUSU6JRWK=
GI-1	M3XYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XEZ2lEPTB;M{muPFY1PyEQvF2=	NH:yZlNUSU6JRWK=
GOTO	NYPuSWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnqWIsxUUN3ME2zPU46OTN7IN88US=>	M4jZS3NCVkeHUh?=
A673	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTRzLkCzOFMh\|ryP	MVfTRW5ITVJ?
KG-1	NUjzemNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPRbIpyUUN3ME20N{4{QTRizszN	NEHoWnlUSU6JRWK=
GP5d	NFj2OG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHkUYdwUUN3ME20OE4xPjZ4IN88US=>	MoDUV2FPT0WU
MFM-223	NYfKUlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\QNFBIUUN3ME20OE4yOjJ6IN88US=>	NV7SPIxqW0GQR1XS
OAW-42	NUn1T3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;QRmlEPTB;NESuNlY1OyEQvF2=	NV;2TWtFW0GQR1XS
C8166	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnqOVh7UUN3ME20OU4xQDJ{IN88US=>	M3XDOHNCVkeHUh?=
LU-99A	NF7ETYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\2ZpZlUUN3ME20Ok4yOzJ{IN88US=>	MYnTRW5ITVJ?
NCI-H23	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zrOWlEPTB;NE[uNVc5PSEQvF2=	NVHh[mhlW0GQR1XS
HO-1-N-1	NXP2WHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz1[\|NKSzVyPUS3MlA6QThizszN	NE\ZOFNUSU6JRWK=
A3-KAW	NF;DW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LoVmlEPTB;NEeuNVAxPyEQvF2=	NET2cXNUSU6JRWK=
CGTH-W-1	NU\h[IRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTR5LkWwOlkh\|ryP	MVPTRW5ITVJ?
DJM-1	M4CzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXSTWM2OD12Nz61OFE{KM7:TR?=	NV\FU5poW0GQR1XS
A101D	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTR5Lk[zOVch\|ryP	NITpZ3FUSU6JRWK=
BB30-HNC	M{f6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLzNmUzUUN3ME20PE4{ODd{IN88US=>	MX;TRW5ITVJ?
T98G	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTR6LkS2N\|Mh\|ryP	NEjzR41USU6JRWK=
NCI-H1573	NF\tPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\GTWM2OD12OT60OFYzKM7:TR?=	MoDRV2FPT0WU
MEG-01	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\DPFFKSzVyPUS5Mlc1OTFizszN	M13qU3NCVkeHUh?=
WM-115	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH31NHBKSzVyPUS5MlkzOjJizszN	NF\Re3JUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	+ Expand Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

+ Expand

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03561870	Not yet recruiting	Recurrent IDH\|Mutant High Grade Glioma	Hospices Civils de Lyon	December 1 2019	Phase 2
NCT03561870	Not yet recruiting	Recurrent IDH\|Mutant High Grade Glioma	Hospices Civils de Lyon	December 1 2019	Phase 2
NCT03741426	Not yet recruiting	Renal Cell Cancer	CCTU- Cancer Theme\|University of Cambridge\|AstraZeneca\|Cancer Research UK\|Cambridge University Hospitals NHS Foundation Trust	July 25 2019	Phase 2
NCT03741426	Not yet recruiting	Renal Cell Cancer	CCTU- Cancer Theme\|University of Cambridge\|AstraZeneca\|Cancer Research UK\|Cambridge University Hospitals NHS Foundation Trust	July 25 2019	Phase 2
NCT03880019	Not yet recruiting	Stage III Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8\|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8	National Cancer Institute (NCI)	June 7 2019	Phase 2
NCT03842228	Not yet recruiting	Advanced Malignant Solid Neoplasm\|ARID1A Gene Mutation\|ATM Gene Mutation\|ATRX Gene Mutation\|BARD1 Gene Mutation\|BRCA1 Gene Mutation\|BRCA2 Gene Mutation\|BRIP1 Gene Mutation\|CDK12 Gene Mutation\|CHEK1 Gene Mutation\|CHEK2 Gene Mutation\|FANCA Gene Mutation\|FANCL Gene Mutation\|Metastatic Malignant Solid Neoplasm\|MRE11 Gene Mutation\|MSH2 Gene Mutation\|PALB2 Gene Mutation\|PARP1 Gene Mutation\|PIK3CA Gene Mutation\|POLD1 Gene Mutation\|PPP2R2A Gene Mutation\|PTEN Gene Mutation\|RAD51B Gene Mutation\|RAD51C Gene Mutation\|RAD51D Gene Mutation\|RAD54L Gene Mutation\|Unresectable Malignant Solid Neoplasm\|XRCC2 Gene Mutation	National Cancer Institute (NCI)	June 10 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products5

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699,PF-01367338) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 119 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 119 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)